{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1533, 
        1542
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1256, 
        1279
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1388, 
        1404
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2259, 
        2279
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2281, 
        2289
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1451, 
        1478
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1480, 
        1490
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1493, 
        1498
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2244, 
        2249
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        546, 
        575
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        577, 
        594
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": ",Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2188, 
        2214
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2216, 
        2234
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1524, 
        1532
      ]
    }
  ], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "FALSE NEGATIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5", 
      "__extent": [
        1632, 
        1633
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Ben,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1635, 
        1662
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1499, 
        1505
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2236, 
        2242
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1507, 
        1512
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20171102_22ABC_CDC_H3,Model - 20171123_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2251, 
        2256
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "", 
      "__annotator__": "Gemma", 
      "__extent": [
        598, 
        600
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1490, 
        1492
      ]
    }
  ], 
  "__text": "MSH|^~\\&|LABCORP-CORP|LABCORP^34D0655059^CLIA|Cancer Registry|State|201706010938|State006|ORU^R01|2017060107093839521000|P|2.3.1\nPID|1||^^^^SS^~11111111^^^^PI^|ALTERNATE ID|TEST^PATIENT^A||19500601|M||2054-5^Black or African American^CDC^^^|1234 Test Road^^ALBANY^NY^12201||^^^^^222^1234567|||||||\nORC|RE||111A1111111||||||||||||||||||Ordering Facility Name^^L|2222 W. Test Road^^Test^TX^77025|^^^^^111^1234567||\nOBR|1||111A1111111|^^^111111^Pathology Report^L|||201705301335|||||||20090115||Ordering Provider Name||||||20170530|||F|||||||\n\n\n\n\n\n\nPath report.gross observation\n\nGross description: \n A. The specimen is received in a formalin-filled container labeled with the patient's name and right breast biopsy 12:30. \n Core pieces: 4 Measurement: 0.8-1.5 cm in length and 0.2 cm in diameter Comments: yellow lobulated fibrofatty, marked blue \n Entirely submitted in cassette(s): 1 \n Time/Date in fixative: placed in formalin at 8:40 AM on 07/21/2017 a cold ischemic time of less than 5 minutes Total fixation time: 6.5 hours \n \n \n /XDB\n\n\nPayment procedure\n\nCPT                            .883051, 883601, 883602, 883603\n\n\nPATHOLOGIST NAME\n\nElectronically signed: Pathologist name, Pathologist\n\n\nDiagnosis ICD code\n\nPathologist provided ICD-10:C50.811\n\n\nPath report.relevant Hx\n\nPre-operative diagnosis: Highly suspicious for malignancy\nPost-operative diagnosis: None provided. \n \n \n .\nClinical history: Palpable breast mass with calcifications .\n\n\nPath report.final diagnosis\n\nDiagnosis:A. RIGHT BREAST, 12:30; BIOPSY: - INVASIVE CARCINOMA WITH INFILTRATIVE FEATURES. - TUMOR SIZE IN THIS CORE SAMPLE: 5 MM. - PRELIMINARY GRADE: 2 (NOTTINGHAM HISTOLOGIC GRADE)   TUBULAR/GLANDULAR DIFFERENTIATION SCORE: 3   NUCLEAR PLEOMORPHISM SCORE: 2   MITOTIC RATE SCORE: 2 \n Note: ER, PR and HER2-neu immunohistochemistry is obtained and results will be issued in an addendum. HER2 FISH will be performed for equivocal results. Final histologic grade and classification should be based on the excised tumor. Results were called to Denise in the Radiology Department on 7/24/17 at 1:45 PM with read back. \n \n XDB/08/03/2017 **********************************************************************\n\n\nPath report.site of origin\n\nMaterial submitted: Breast, right, 12:30\n\n\nPath report.comments\n\nComment:CASE: PATIENT: Final Diagnosis performed by  Electronically signed 7/24/2017 1:50:28PM \n \n The electronic signature indicates that the named Attending Pathologist has evaluated the specimen \n Technical component performed at LabCorp, 1447 York Court, Burlington, NC 27215 Lab: 800-762-4344 Dir: William F. Hancock, MD \n Professional component performed at LabCorp, Alamance Regional Medical Center, 1240 Huffman Mill Rd, Burlington, NC 27215 Lab: 336-538-7833 Dir: Tara C. Rubinas, MD \n \n \n Breast Biomarker Reporting Template Specimens InvolvedA: Breast, right, 12:30 \n Breast, Biomarker Reporting Template BREAST BIOMARKER TESTS Test(s) Performed: Estrogen Receptor (ER) Results: POSITIVE  Range: >90% Test Type:   FDA cleared (Ventana) Primary Antibody:  SP1 Progesterone Receptor (PgR) Results: POSITIVE  Range: 11-50% Test Type:   FDA cleared (Ventana) Primary Antibody:  1E2 HER2 (ERBB2) by Immunohistochemistry (IHC) Results: Equivocal (Score 2+) Percentage of Cells with Uniform Intense Complete Membrane Staining: 1% Test Type:   Food and Drug Administration (FDA) cleared (DAKO) Primary Antibody:  HercepTest METHODS Cold Ischemia and Fixation Times: Meet requirements specified in the latest version of ASCO / CAP guidelines Cold ischemia time (mins)::  4 Time of fixation (hours)::  6.5 Testing performed on block number(s) (specify):: A1 Fixative: Formalin Image Analysis:   Not performed \n \n \n \n \n \n Addendum #1 performed by  Electronically signed 7/26/2017 1:34:24PM \n \n Technical component performed at LabCorp, 1447 York Court, Burlington, NC 27215 Lab: 800-762-4344 Dir: William F. Hancock, MD \n Professional component performed at LabCorp, Alamance Regional Medical Center, 1240 Huffman Mill Rd, Burlington, NC 27215 Lab: 336-538-7833 Dir: Tara C. Rubinas, MD \n \n \n Breast Biomarker Reporting Template Specimens InvolvedA: Breast, right, 12:30 \n Breast, Biomarker Reporting Template BREAST BIOMARKER TESTS Test(s) Performed: HER2 (ERBB2) by In Situ Hybridization (ISH) Results: Negative (not amplified) Number of Observers:   2 Number of Invasive Tumor Cells Counted: 40 Method:  Using dual probe assay Average Number of HER2 Signals per Cell:   2 Average Number of CEP17 Signals per Cell:  1.9 HER2 / CEP17 Ratio: 1.07 Test Type: Food and Drug Administration (FDA) cleared (DAKO HER@ IQFISH pharmDX) METHODS Cold Ischemia and Fixation Times: Meet requirements specified in the latest version of ASCO / CAP guidelines Cold ischemia time (mins)::  4 Time of fixation (hours)::  6.5 Testing performed on block number(s) (specify):: A1 Fixative: Formalin Image Analysis:   Not performed \n \n \n \n \n Addendum #2 performed by  Electronically signed 8/3/2017 2:14:13PM \n \n \n Technical component performed at LabCorp, 1447 York Court, Burlington, NC 27215 Lab: 800-762-4344 Dir: William F. Hancock, MD \n Professional component performed at LabCorp, Alamance Regional Medical Center, 1240 Huffman Mill Rd, Burlington, NC 27215 Lab: 336-538-7833 Dir: Tara C. Rubinas, MD .\n\n\n"
}